Cynata Therapeutics Limited has released initial data from its Phase 1 clinical trial of CYP-006TK for diabetic foot ulcers (DFU).

Kura Oncology has initiated its Phase 1 clinical trial, KOMET-008, which involves administering the menin inhibitor ziftomenib in tandem with gilteritinib.

Biora Therapeutics has achieved a significant milestone in its clinical trials for a novel drug-device combination, BT-600.

On February 16, 2024, a significant milestone in cancer treatment was achieved with the FDA's approval of the first-ever single-session cell therapy for solid tumors, marking an innovative step forward in the field.

RECCE® 327, when administered daily or every other day for two weeks, has proven to be both safe and well-tolerated.

Gain Therapeutics has commenced the Multiple Ascending Dose (MAD) phase of its Phase 1 clinical trial for GT-02287, a potential treatment for GBA1 Parkinson's disease.

Curadev Pharma has achieved a crucial step in its cancer treatment research with the successful completion of the initial treatment phase for a patient administered CRD3874-SI

Ionis Pharmaceuticals, Inc. and Biogen Inc. have decided to discontinue the development of BIIB105 (ION541) following the initial outcomes from the Phase 1/2 ALSpire trial.

On May 15th, the journal Nature published a research paper titled "GLP-1-directed NMDA receptor antagonism for obesity treatment" by the Novo Nordisk team.

Carisma Therapeutics reports initial patient dosed in Phase 1 study of CT-0525, an innovative HER2-focused CAR-monocyte therapy.

May 21st latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The FDA has greenlit Imdelltra™ (tarlatamab-dlle), marking the first T-cell engager therapy for extensive-stage small cell lung cancer.